Back to Journals » Cancer Management and Research » Volume 13

WNT5a in Colorectal Cancer: Research Progress and Challenges

Authors Sun G, Wu L, Sun G, Shi X, Cao H, Tang W

Received 31 October 2020

Accepted for publication 17 February 2021

Published 16 March 2021 Volume 2021:13 Pages 2483—2498

DOI https://doi.org/10.2147/CMAR.S289819

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Dr Beicheng Sun


Guangshun Sun,1,* Liangliang Wu,1,* Guoqiang Sun,1 Xuesong Shi,1 Hongyong Cao,1 Weiwei Tang2

1Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China; 2Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hongyong Cao; Weiwei Tang Email [email protected]; [email protected]

Abstract: Despite the clinical development of new adjuvant and neoadjuvant chemotherapy drugs, colorectal cancer is still one of the leading causes of cancer-related death in human beings. WNT5a, an autocrine and paracrine β-catenin independent ligand, has been shown to induce tumor inhibition and carcinogenic signals, depending on the type of cancer. In patients with colorectal cancer, WNT5a triggers a variety of downstream signaling pathways, which mainly affect the migration and invasion of tumor cells. This article reviews the mechanism and therapeutic potential of WNT5a in colorectal cancer. In short, an in-depth understanding of the role of WNT5a in colorectal cancer is very helpful to better deal with this disease.

Keywords: WNT5a, colorectal cancer, WNT, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]